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Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, 
tool molecules are required to demonstrate that a ligand can have a disease-modifying effect. Currently, as tools are reported for 
only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment 
screening offers an efficient approach to explore chemical space, however, it remains challenging to develop techniques that are 
both sufficiently high-throughput and sensitive. We present a fragment screening platform, termed PhABits (PhotoAffinity Bits), 
which utilises a library of photoreactive fragments to covalently capture fragment-protein interactions. Hits can be profiled to de-
termine potency and site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify 
novel hit matter. We envision that the PhABits will be widely applicable to novel protein targets, identifying starting points in the 
development of therapeutics.   
INTRODUCTION 
Advances in human genome sequencing technologies now 
enable genome-wide association studies (GWAS) across large 
populations, providing insights into the genetic origins of dis-
ease.1 The combination of GWAS with functional genomic anal-
yses (e.g. CRISPR-Cas9 screens), allows identification of path-
ways and targets with therapeutic potential.2 Prior to the initi-
ation of drug discovery efforts, validation of these targets is re-
quired, often involving the use of chemogenomic tool mole-
cules to build confidence that a ligand can cause a disease-
modifying effect.3-4 For a large proportion of the proteome no 
tool molecules have been reported, therefore, platforms for 
rapid ligand discovery are required to enable translation of ge-
nomic analyses into medicines.5 
The scientific community has typically relied upon high-
throughput screening (HTS) for the identification of tool mole-
cules, which is often slow and resource intensive.6 Binding-
driven assays, such as Affinity Selection Mass Spectrometry 
(ASMS) and DNA Encoded Libraries (DELs) have recently been 
developed to accelerate ligand discovery through the efficient 
screening of large libraries (106–1012 compounds).7-16 While 
these approaches are powerful, they employ lead-like libraries 
(MW>300) that generate hits that may suffer from sub-optimal 
ligand efficiency and can prove challenging to optimise. Addi-
tionally, the upfront investment in library generation, and sam-
ple handling, limits the accessibility of this screening strategy 
to the broader scientific community.6 
Fragment-based lead discovery (FBLD) offers a complemen-
tary approach. The use of low molecular weight fragments 
enables effective coverage of chemical space with a smaller 
number of molecules, to identify weak but highly efficient in-
teractions.17-19 Fragment hits can subsequently be optimised 
into more potent binders with drug-like properties, as has 
been demonstrated by the discovery of numerous clinical can-
didates by FBLD (e.g. FDA approved therapeutics: vemuraf-
enib,20 venetoclax,21 and erdafitinib22).23-25 The primary chal-
lenge associated with fragment screening is the requirement 
for highly sensitive screening technologies to detect weak frag-
ment-protein interactions.26 Historically, fragment screening 
has relied upon NMR monitoring techniques and surface plas-
mon resonance (SPR), but these approaches are often resource 
intensive.27 Furthermore, methods for hit validation and bind-
ing site identification (e.g. structural studies) are then required 
to enable the appropriate triaging and optimisation of frag-
ment hits. Evolution of next generation fragment screening 
technologies would facilitate more rapid discovery of protein 
ligands. 
The use of electrophilic fragment libraries has emerged 
within chemical biology as a powerful approach for the identi-
fication of fragment-protein interactions.28-30 Electrophilic 
fragments covalently modify the protein, facilitating the use of 
intact protein liquid chromatography-mass spectrometry (LC-
MS) for rapid and robust screening of libraries (~103 com-
pounds) to identify binders.28 Covalent fragments that target 
cysteine residues have been identified and successfully opti-
mised to cell-active tool compounds for proteins including e.g. 
HOIP and KRas.31-32 A limitation of these libraries is that a cys-
teine residue must be present in the vicinity of the binding site, 
and therefore, only a subset of proteins can be targeted.33-34 
 Strategies that enable reaction with a wider range of amino 
acid residues would expand the number of ‘ligandable’ pockets 
that can be pursued, and broaden the applicability of the ap-
proach.  
Photoaffinity labelling has proved useful for the capture of 
reversible ligand-protein interactions.35-37 Upon irradiation 
with UV light, photoreactive warheads can covalently crosslink 
to proximal protein residues,  providing a broad method for 
the covalent capture of reversible ligand-protein binding. Cra-
vatt and co-workers recently reported the use of photoreac-
tive fragments for the identification of fragment-protein inter-
actions in live cells.38 This proof-of-concept study highlights an 
opportunity to screen libraries of fragments in cells to build a 
fragment-protein interaction database across the proteome. 
However, the current throughput and sensitivity of the MS-
based proteomic readout, as well as the large dynamic range 
of the proteome, limits the broad adoption of this approach. 
We hypothesised that the use of photoreactive fragment li-
braries in a biochemical setting would improve the throughput 
and enable targeted screening against proteins of interest. 
Such an approach would build upon electrophilic fragments, 
with the advantage of being applicable to all protein pockets.  
Here we report a fragment screening platform, PhABits, 
where a library of photoreactive fragments are screened in the 
presence of purified protein. Hits can be detected by intact 
protein LC-MS enabling identification of known and new 
chemotypes. Follow-up studies allow determination of binding 
affinities and the sites of crosslinking. In order to develop frag-
ments into more potent binders, hit PhABits can subsequently 
be employed as reporter ligands in a MS-based displacement 
assay. The PhABit platform enables efficient identification of 
fragment-protein interactions for binding sites that do not con-
tain cysteine residues. Moreover, the approach enabled rapid 
detection of fragment hits for KRas4BG12D, which is widely con-
sidered to be a poorly tractable target.39  
 
RESULTS 
Assembling a photoreactive fragment library 
We anticipated that irradiation of a library of photoreactive 
fragments in the presence of purified protein, would enable 
photocapture of weak non-covalent fragment-protein binding, 
which could then be detected by intact mass spectrometry 
(Figure 1A). The photocapture event occurs as a two-step pro-
cess: first, non-covalent fragment-protein binding, character-
ised by a KD, and second, UV-induced photocrosslinking to cap-
ture any reversible interactions, characterised by a crosslinking 
efficiency. Photoreactive intermediates (e.g. carbenes) rapidly 
crosslink or are quenched, and therefore photocrosslinking 
represents a snapshot of the status of the reversible binding 
equilibrium (Figure 1C). This contrasts with electrophilic librar-
ies where the warhead has a longer lifetime and the extent of 
modification is time-dependent. A small alkyl diazirine photo-
reactive group was selected as the crosslinking moiety to min-
imise any perturbation to binding of the fragment warhead.40-
41 A diverse set of 650 amine containing fragments was se-
lected from the GSK amine collection (aromatic ring count ≤2; 
H-bond donors/acceptors ≤4; heavy atoms ≤15; MW≤200), 
using clustering on chemical fingerprints (Figure 1B). A high-
throughput synthetic protocol was employed to couple the 
amine fragments to a carboxylic acid-functionalised diazirine 
(R1). Reaction mixtures were directly purified by strong cation 
exchange (SCX) cartridge, followed by deprotection and re-
verse phase chromatography where required. This workflow 
enabled the rapid generation of a library of 556 PhABits (Figure 
1B). Analysis of the library’s properties confirmed that the frag-
ments covered a chemical space comparable to other commer-
cially available libraries (Supplementary Figure 1).28 
 
Photoreactive fragment screening  
The PhABit library was screened against a diverse panel of 
six proteins: myoglobin, lysozyme, carbonic anhydrase, BRD4-
BD1, BCL6 and KRas4BG12D. The library was incubated with re-
combinant protein (1 µM, 4 °C, 15 min, 200 µM PhABit) before 
irradiation with UV light (302 nm, 10 min), and direct analysis 
by intact protein LC-MS (Figure 1C). The resulting mass spectra 
were analysed to identify PhABits that had covalently modified 
the protein, leading to an additional peak at a mass of [pro-
tein+PhABit-N2]. A range of crosslinking yields (0–53%) were 
observed and hits were classed as strong (>5% crosslinking) or 
moderate (1.5–5% crosslinking). In general, the crosslinking 
yields for hits were low, which could have resulted from either 
low site occupancy or poor crosslinking due to orientation of 
the diazirine / quenching of the carbene. Consequently, cross-
linking yield was not used as a measure of binding affinity and 
all hits were followed up. A small number of PhABits (~1%) 
showed multiple crosslinking events, suggesting that the 
PhABit was bound to a number of different sites on the pro-
tein, or potentially formed a long-lived reactive species ena-
bling multiple modifications to take place via diffusion-based 
crosslinking. This behaviour was indicative of non-selective 
binding and therefore not considered hits (Figure 1D).  
Analysis of the screens generated variable hit rates across 
the proteins with lysozyme yielding the highest number of 
crosslinking PhABits (47%), in contrast to myoglobin with very 
few binders (<3%) (Figure 1E). A number of warheads previ-
ously reported to bind to the proteins were identified as hits, 
including two dimethyl isoxazole fragments for BRD4-BD1 (see 
inhibitor iBET-15142), and a series of sulfonamides for carbonic 
anhydrase (see dorzolamide,43 methazolamide44 and acetazo-
lamide45). These hits provided early validation that the PhABit 
screen could identify true fragment binders.  
 
Promiscuity and non-specific crosslinking 
A key concern in fragment screening is deconvolution of spe-
cific versus non-specific interactions. In traditional fragment 
screening, the latter is usually associated with high lipophilicity 
or low solubility of the fragment. Electrophilic fragment  
screens can yield non-selective hits due to high reactivity of the 
electrophilic warhead, leading to labelling of surface-exposed 
cysteine residues.28 An analogous consideration for pho-
toaffinity labelling is that the reactive intermediate formed 
upon irradiation should be appropriately short-lived to avoid 
diffusion-based crosslinking that is not driven by binding affin-
ity. The majority of the PhABits did not crosslink to the proteins 
screened, indicating that the reactive intermediate was rapidly 
 quenched. However, ten PhABits were found to crosslink to all 
proteins screened and 58 crosslinked to at least four proteins. 
These could represent privileged scaffolds that are accommo-
dated by many protein pockets, or be due to non-specific 
crosslinking either through lipophilic interactions with the pro-
tein or formation of long-lived reactive species. 
To further investigate the specificity of the 89 PhABits that 
crosslinked to BRD4-BD1, the screen was repeated in the pres-
ence of the BET inhibitor JQ1, which binds within the acetyl ly-
sine pocket.46 JQ1 (10 µM) was incubated with hit PhABits (200 
µM) and BRD4-BD1 (1 µM) before irradiation and analysis by 
LC-MS (Figure 2A). For 68 PhABits, >50% displacement was ob-
served, indicating that these fragments bind selectively to the 
acetyl lysine binding pocket. Of the remaining 21 fragments 
that were not displaced, 19 crosslinked to at least three of the 
other tested proteins, suggesting non-specific crosslinking. 
Physicochemical analysis of these fragments did not highlight 
any properties that would typically cause non-specific binding, 
e.g. high lipophilicity or low solubility (Supplementary Figure 
2). Therefore, it may be that these PhABits form a long-lived 
intermediate, leading to diffusion-induced crosslinking. In all 
subsequent screening analyses these PhABits were omitted.   
 
Confirmation and characterisation of BRD4 PhABit hits 
BRD4-BD1 was selected for in-depth analysis of the screen-
ing results and follow-up studies on the hits. BRD4 is a member 
Figure 1: Photoreactive fragment screening. A: General structure of the PhABit compounds, highlighting the three key functionalities. B: 
Selection of the amines for the PhABit library and subsequent one-step synthetic protocol, giving access to 556 PhABits. C: Schematic of 
workflow used to screen the PhABit platform against recombinant proteins of interest. Proteins (1 µM) are incubated (4 °C, 15 min) with 
PhABit (200 µM) before UV irradiation (302 nm, 10 min) and analysis by intact LC-MS. D: Examples of spectra obtained during analysis of 
the PhABit screen of BRD4-BD1, (*) indicates the expected mass of BRD4-BD1 and crosslinked PhABit. E: Heat map of the PhABit screen 
against recombinant proteins: myoglobin, lysozyme, carbonic anhydrase, KRas4BG12D, BRD4-BD1 and BCL6. Known binding motifs to both 
BRD4-BD1 and carbonic anhydrase that were identified in the screens are highlighted.    
 
 of the bromodomain and extra-terminal domain (BET) family 
of proteins,47 which are involved in epigenetic regulation and 
are potential therapeutic targets for the treatment of disease, 
including cancer and inflammation.48-49 The BRD4-BD1 PhABit 
screen afforded 68 hits (12%) that were displaced by JQ1, 
which gave strong (13), and moderate (55) crosslinking.  Hits 
included the aforementioned dimethyl isoxazoles 3 and 4, 
other 5-membered heterocycles (e.g. 6 and 7), acetyl lysine mi-
metics (1 and 9) and less typical structures (5 and 8), which 
could represent novel binding motifs for the acetyl lysine 
pocket (Figure 2B). Orthogonal confirmation of non-covalent 
binding to the acetyl lysine binding site was performed using a 
BRD4-BD1 TR-FRET competition assay. Six of the nine hits (2–
4, 6 and 8–9) were found to inhibit bromodomain-substrate 
binding with weak to moderate affinity (pIC50 values 4.0–5.7, 
Figure 2C).  
In order to identify hit fragments in the development of 
therapeutics, the contribution of the photoreactive warhead 
to binding affinity was investigated. A primary goal of the 
PhABit platform was to identify hits that can subsequently be 
developed without the photoaffinity label. A key considera-
tion, therefore, was the contribution of the photoreactive war-
head to the binding affinity. Analogues of hit PhABits were syn-
thesised with acetyl- and butanoyl-amides in place of the pho-
toreactive group to explore the impact this had on potency 
(10–19, Supplementary Figure 3). A decrease of less than 0.6 
log units in the TR-FRET assay was observed upon truncating 
to the acetylamide analogues, and potency was typically recov-
ered in the butanoylamide analogues (Figure 2C). The reten-
tion of potency upon removal of the photoreactive moiety con-
firmed binding was driven by reversible fragment-protein in-
teractions.  
The PhABit screen proved straightforward to implement, al-
lowing expedient screening via LC-MS, to identify fragment-
protein interactions. The PhABits were directly applied to a 
panel of proteins without the requirement for assay optimisa-
tion, which is a distinct advantage over many other fragment 
screening strategies. Further, none of the proteins screened 
here contain an exposed cysteine, thus highlighting the ad-
vantage of photoreactive fragments over cysteine-reactive ap-
proaches, by now enabling the identification of binders for any 
ligandable protein pocket. 
 
FOLLOW-UP STUDIES 
Determination of potency of hit PhABits 
We anticipated that a key feature of the PhABit platform 
would be the opportunity to perform follow-up studies to fur-
ther characterise the hits and enable appropriate triaging. 
First, concentration-response studies were performed to 
measure PhABit binding affinity. Hit PhABits were incubated at 
a range of concentrations with BRD4-BD1 (1 µM) before irradi-
ation and analysis by LC-MS. In all cases, a concentration-de-
pendent reduction in the crosslinking yield was observed (Fig-
ure 3A). The resulting curves could be fit to calculate pKD val-
ues, and enabled deconvolution of the crosslinking event; the 
gradient of the curve is determined by the non-covalent KD of 
the fragment, while the plateau represents the maximum 
crosslinking efficiency of the PhABit (Figure 3B). Importantly, 
this maximum is independent of the potency of the fragment, 
and only measures crosslinking efficiency versus other carbene 
quenching processes. Thus, concentration-response studies 
enabled differentiation of weak binders with high crosslinking 
Figure 2: Confirmation and characterisation of BRD4 PhABit hits. A: Intact MS spectra of single shot displacement of two PhABits showing 
without JQ1 (blue) and pre-incubation with JQ1 (10 µM) (red).  B: Intact MS spectra and structures of hit PhABits for BRD4-BD1. C: TR-FRET 
data for selected PhABits and acetyl- and butanoyl-amide analogues.    
 
 efficiency (e.g. 1) and potent binders with poor crosslinking ef-
ficiency (e.g. 3). To validate the PhABit-generated pKD values, 
the fragments were also screened by SPR (pKD) and TR-FRET 
(pIC50) assay, which showed good correlation (SPR R2=0.82 and 
TR-FRET R2=0.90, Figure 3C). The concentration-response 
study thus offers an expedient method for determining the po-
tency of hit PhABits.  
 
Determination of site of binding / crosslinking 
A second feature of covalent crosslinking is that it enables 
determination of the site of binding without recourse to crys-
tallography. The site of binding can be determined either by 
competition, where suitable ligands with known binding loca-
tion are available (e.g. JQ1 as demonstrated above), or by elu-
cidation of the site of crosslinking by LC-MS/MS analysis. This 
latter approach would be particularly powerful for proteins 
without known binders or crystallography. PhABit 2 was se-
lected to explore this technique with BRD4-BD1. Crosslinked 
samples were digested using trypsin/LysC and the resulting 
peptides analysed by LC-MS/MS. The peptide 
101PGD*DIVLMAEALEK114 was identified as carrying a modifica-
tion on D103, which was not observed in the non-irradiated 
control sample (Figure 3D). This residue is at the edge of the 
acetyl lysine binding site, and ideally situated for crosslinking. 
The site of crosslinking was also determined for 3, 4 and 6, 
which were found to crosslink to a neighbouring aspartic acid 
residue, D104, suggesting a different orientation of the diazir-
ine, but consistent with binding to the same pocket (Supple-
mentary Figure 4). The binding of PhABit 2 was further investi-
gated by elucidation of a co-crystal structure of 2 with BRD4-
BD1 (without UV irradiation).  The structure showed the PhABit 
warhead binding in the acetyl lysine pocket, forming a hydro-
gen bond to asparginine N140, with the diazirine group ori-
ented out of the pocket and directly adjacent to residue D103, 
consistent with the observed crosslinking to this residue (Fig-
ure 3E). 
Follow-up studies enabled characterisation of potency and 
binding sites of hit PhABits. The direct measurement of PhABit 
KD values that matched those obtained in orthogonal assays is 
significant, as it enables hits to be prioritised without the de-
velopment of secondary screens. Further, LC-MS/MS analysis 
enabled identification of the residue of crosslinking, from 
which the site of binding could be inferred. These follow-up 
studies will be particularly impactful in the case of emerging 
proteins where assays and crystallography are not available, 
allowing characterisation and progression of hits on the PhABit 
platform alone. 
 
Figure 3: Follow-up studies for hit validation. A: Overlay of the intact MS spectra of 2 in a concentration-response manner, crosslinked to 
BRD4-BD1 following irradiation (302 nm, 10 min). B: Plots of the crosslinking yields of hit PhABits treated in concentration-response to 
BRD4-BD1, error bars represent SEM across three replicates. This data can be used to generate pKD values for each PhABit. C: Comparison 
of potencies of five hit PhABits generated by concentration-response (pKD values used) (n=3) vs TR-FRET and SPR assays (n=3). The lines of 
best fit are plotted (SPR R2=0.82 and TR-FRET R2=0.90). D: Following incubation of 2 with BRD4-BD1 and irradiation at 302 nm for 5 mins, 
the sample was reduced, treated with iodoacetamide and digested using trypsin and LysC. Analysis by LC-MS/MS (mass of [2-N2] on any 
residue as a variable modification) identified peptide 101PGD*DIVLMAEALEK114 crosslinked to 2, indicating D103 as the site of crosslinking. 
E: Co-crystal structure of 2 bound to BRD4-BD1 pre-irradiation, showing the proximity of the diazirine to the aspartic acid residue which is 
identified as the site of crosslinking.  
 
 Development of a fragment-based PROTAC for BRD4 
It was anticipated that the PhABit platform could be an ex-
pedient approach to identify warheads for the development of 
bifunctional molecules, such as PROteolysis TArgeting Chime-
ras (PROTACs). PROTACs have recently emerged as a therapeu-
tic strategy, inducing protein degradation by hijacking compo-
nents of the ubiquitin-proteasome system.50 Three PROTACs 
(P1-P3), derived from PhABits 3, 4 and 8, were synthesised 
containing a PEG linker conjugated to a VHL-ligase binder (Fig-
ure 4A; for synthesis see Supplementary Figure 5).50 Degrada-
tion of BRD4 was subsequently measured in HEK293 cells using 
a HiBiT assay protocol.51-52 The higher affinity PROTACs P1 
(pIC50=5.5) and P2 (pIC50=5.9) induced degradation above 1 µM 
(Figure 4B), while PROTAC P3 (pIC50=4.7), did not degrade 
BRD4 up to 10 µM, suggesting insufficient fragment affinity. 
Analysis of the cellular ATP levels indicated that the PROTAC 
ligands did not inhibit cell growth. Additionally, pre-treatment 
of the cells with epoxomicin (proteasome inhibitor) reduced 
degradation of BRD4, supporting degradation via the pro-
teasome (Supplementary Figure 6). The experiment thus high-
lights that more potent PhABits could be directly employed for 
the development of PROTACs, to degrade proteins by recruit-
ing components of the ubiquitin-proteasome system. Since the 
PhABit platform identifies binders and not necessarily inhibi-
tors, coupling this screening methodology with the generation 
of PROTACs could be an attractive strategy to enable degrada-
tion of proteins where inhibition proves challenging (e.g. pro-
tein-protein interactions (PPIs) and transcription factors). 
 
PHOTOAFFINITY SCREENING TECHNOLOGY 
In the validation of protein targets of interest, rapid devel-
opment of fragment hits towards more potent tool molecules 
is essential. It was anticipated that hits from the PhABit screen 
could be used as reporters for site-specific displacement as-
says to enable immediate screening. Compounds that compete 
with the reporter PhABit would induce a concentration-de-
pendent reduction in crosslinking, enabling calculation of pIC50 
values (Figure 5A).53 A proof-of-concept study was performed 
using PhABit 2 to develop a binding assay for BRD4-BD1 (Figure 
5B). A library of ~1000 compounds was selected based on a 
similarity search (Tanimoto, >0.7, MW<400 Da) from the hit 
PhABits identified previously (1–9). The compounds were incu-
bated with PhABit 2 and BRD4-BD1 before irradiation and anal-
ysis by LC-MS to determine crosslinking yield. A range of cross-
linking inhibition was observed from 1–100%, with >50% ob-
served for 208 compounds (21% of the total screen) (Figure 
5C). The majority of these hits were derived from dimethyli-
soxazole PhABits 3 and 4, consistent with the presence of this 
motif in a number of BET targeting series in the GSK compound 
collection. The remaining 40 hit compounds (20–59) were de-
rived from PhABits 2, 7, 8 and 9 and grouped into four chemical 
series (Figure 5D). Compounds 22 and 28 are structurally re-
lated to the pan-bromodomain binder bromosporin and had 
previously been identified as binding to BRD4-BD1. Compound 
58 mimics the acetylated native ligand and relates to other re-
ported acetyl lysine mimetics, while compound 40 does not re-
semble known BRD4 binders.  
Determination of compound potency using the PhABit dis-
placement assay could be achieved using concentration-re-
sponse studies. However, advancement from single concentra-
tion screening to concentration-response measurements 
(pIC50) was limited by the throughput of LC-MS analysis (7.7 
min per sample).  The protocol was therefore transferred to 
RapidFireTM MS, which uses a desalting cartridge rather than 
liquid chromatography, enabling analysis at a rate of just 12 
seconds per sample. This acceleration in throughput signifi-
cantly improved the scope of the screening approach.  
The 40 selected compounds from the single concentration 
screen were followed-up in concentration-response mode 
(100–1.56 µM) with analysis by RapidFireTM MS. The crosslink-
ing yield was found to decrease with increasing concentration 
of elaborated compounds, consistent with competitive dis-
placement (Figure 5E). The data showed good reproducibility 
across three replicates and the pIC50 values generated were 
measured across a range of 4–6 (Figure 5F). Values were cor-
rected using the Cheng-Prusoff equation to obtain pKi values, 
based on the pKD value of 2 measured previously (pKD=3.7, Fig-
ure 3B/C). To validate the resulting binding affinities, the 40 
compounds were also screened in the TR-FRET assay. The as-
says showed good correlation (R2=0.72) confirming that the 
PhABit-based displacement screen was a reliable screening 
method (Figure 5G).  
The direct employment of hit PhABits as reporters in a pho-
toaffinity displacement assay is a key advantage of the plat-
form, enabling the screening of elaborated compound librar-
ies. The adoption of RapidFireTM-MS provided a crucial increase 
in the throughput of the assay enabling rapid progression to-
ward more potent tool molecules, on a timescale and resource 
load that competes with traditional assay development.  
 
APPLICATION TO OTHER TARGETS 
To explore the range of applicability of the PhABit platform, 
we subsequently applied it to KRas, which has been widely re-
ported as a protein with low tractability towards small mole-
cule binders.39 KRas oncogenic driver mutations are found  in 
30% of cancers. The mutations result in constitutive activation 
of KRas and downstream signalling pathways which promote 
Figure 4: Development of a fragment-based PROTAC for BRD4. A: 
Structures of the VHL-BRD4 PhABit-derived PROTACs P1-P3, and 
corresponding TR-FRET-derived pIC50 values. B: Degradation 
curves of P1-P3 as measured in the HiBiT assay. P1 and P2 show a 
maximum degradation of 28% and 16% respectively (n=2).  
 uncontrolled cell proliferation and survival.54 The inhibition of 
KRas has been widely investigated for the development of on-
cology therapeutics, however, due to the lack of well-defined 
binding pockets on the protein it has proved extremely chal-
lenging to develop potent ligands.54-57 Some success has been 
reported using fragment screening, which enabled 
Figure 5: Photoaffinity displacement assay. A: Schematic of the displacement assay. Protein and PhABit are incubated with increasing 
concentrations of competitive inhibitor before UV irradiation and analysis by intact MS. B: Elaborated compounds were generated from a 
similarity search on nine hit PhABits (1-9). These were screened at a single concentration (100 µM) to identify 40 hit compounds that 
showed >50% inhibition of crosslinking of 2 to BRD4-BD1. C: Summary of the similarity search-based compound selection to identify com-
pounds more potent than the original hit PhABits. D: Example compounds from the four chemical series that have been identified. E: 
Concentration-response spectra of 2 crosslinked to BRD4 in the presence of increasing concentrations of competitive inhibitor 22. F: Con-
centration-response curves generated for four compounds analysed by the displacement assay. Normalised crosslinking yield of 2+BRD4-
BD1 is plotted against -log[inhibitor](M), error bars represent SEM across three replicates. G: Comparison of pIC50 values generated by the 
displacement assay (n=3) versus TR-FRET assay (an additional 20 compounds showed pIC50 values beyond the lower limit of the assays), 
line of best fit in red (R2=0.72).  
 
 identification of micromolar, and recently submicromolar, lig-
ands to a shallow pocket between the switch I/II regions of 
KRas.57 KRas fragment screening has typically employed HSQC 
NMR with 15N-labelled protein, which is resource intensive. We 
explored whether the PhABit library could provide an alterna-
tive approach to identify fragment binders and their binding 
sites.     
KRas4BG12D was incubated with the PhABit library (1 µM, 4 
°C, 15 min, 200 µM PhABit) before irradiation and analysis by 
LC-MS. The results were compared to the screening of BRD4-
BD1 and BCL6, to identify 11 unique hits for KRas, of which four 
were of particular interest (60-63, Figure 6A/B). These hits ex-
emplified two chemotypes: 2-heterocyclic pyridines (60 and 
61) and an indole warhead (62 and 63). The indoles are similar 
to previously reported KRas binders identified by NMR studies, 
suggesting the screen has identified true hits.54 The 2-
heterocyclic pyridines do not resemble known ligands and 
therefore represent novel KRas binding motifs.  
The binding site of indole hit 62 was explored by LC-MS/MS 
analysis of crosslinked KRas4BG12D. Three modified peptides 
were identified corresponding to crosslinking on three differ-
ent residues on the same peptide (57DTAGQE*E*Y*SAMoxR68, 
Figure 6C). These residues, E62, E63 and Y64, lie at the loop of 
the switch I/II region, directly adjacent to the binding site of 
ligands reported previously (e.g. 64, PDB ID:4EPY, Figure 6D).54 
This pocket is of functional significance in interacting with 
SOS1/2, the guanine nucleotide exchange factors (GEFs), 
which promote formation of the active KRas state.39 Thus, the 
PhABit platform enabled expedient identification of fragment 
binders to a protein of low tractability, and provided insight 
into the binding site of hit PhABits without the need for re-
course to NMR and crystallography.  
Figure 6: Application of the PhABit platform to KRas. A: Intact MS spectra of hit PhABits for KRas following irradiation with UV light. B: 
Structures of the four selected hit PhABits for KRasG12D. C: LC-MS/MS spectrum of the tryptic derived peptide 58DTAQE*E*Y*SAMR69 cross-
linked to 62 indicating E63, E64 and Y65 as the sites of crosslinking. D: Co-crystal structure of compound 64 bound to KRasG12V, highlighting 
the amino acid residues which underwent crosslinking with 62. E: Compounds identified previously as binding to KRasG12D. F: Concentra-
tion-response curves generated for 64 and 65 analysed by displacement assay. Normalised crosslinking yield of 62+KRasG12D is plotted 
against -log[inhibitor](M), error bars represent SEM across three replicates.  
 
 A challenge associated with KRas has been access to assays 
to enable efficient screening of compounds libraries. We ex-
plored the use of the photoaffinity displacement assay to 
measure IC50 values of compounds of interest. A range of con-
centrations of previously reported KRas binders 64 and 65 (Fig-
ure 6E) were incubated with KRas4BG12D (1 µM) and hit PhABit 
62 (1 mM) before irradiation. The crosslinking yields were de-
termined by LC-MS to afford the expected concentration-de-
pendent decrease in crosslinking (Figure 6F). The generated 
IC50 values of 170 µM (64) and 90 µM (65) were consistent with 
reported values (64 = 340 µM, and 65 = 190 µM), which were 
determined by HSQC NMR using 15N-labelled KRasG12D.54 This 
displacement assay therefore provides an efficient method for 
screening ligands against the switch I/II region binding site. 
Identification of KRas fragment binders using the PhABit 
platform has demonstrated its utility as a screening approach 
for challenging protein targets. Rapid follow-up studies by LC-
MS/MS enabled straightforward identification of the site of 
binding, which was consistent with previously reported crys-
tallographic studies. Additionally, hits provided immediate ac-
cess to an assay to profile published compounds, which could 
prove useful for further KRas inhibitor development studies.  
 
CONCLUSIONS 
We describe a fragment screening platform (PhABits) that 
uses a photoreactive group (diazirine) to capture fragment-
protein binding. The approach is straightforward to implement 
and can be directly applied to purified proteins without the re-
quirements of more traditional assay development. The 
PhABits, along with other covalent fragment approaches, offer 
rapid assessment of tractability and tool generation on time-
scales suitable for application to the large numbers of targets 
emerging from functional genomics analyses. In this way, the 
platform complements other binding assay approaches, such 
as ASMS and DELs, which are not typically compatible with 
fragments.  
In addition to identifying hits, the platform enables determi-
nation of potency and site of binding, providing actionable in-
formation before optimisation of secondary assays and crystal-
lography. Furthermore, hit PhABits can immediately be used as 
reporters in displacement assays to screen libraries of com-
pounds to identify more potent binders in a site-specific man-
ner. These tools may also prove valuable in qualifying hits from 
complementary approaches, such as DELs and ASMS. We have 
also demonstrated their utility for rapid access to PROTAC lig-
ands. 
A limitation of the approach is that proteins must first be 
amenable to analysis by MS. Additionally, low crosslinking 
yields can inhibit the detection of hits. Advances in protein 
mass spectrometry and development of photoreactive groups 
with improved crosslinking yields will improve the applicability 
of the approach. We anticipate the accessibility of the PhABit 
workflow will enable efficient identification of fragment bind-
ers to emerging biological targets. Furthermore, the informa-
tive output of the various follow-up studies will facilitate the 
rapid development of tool molecules for disease biology and 
target validation studies. 
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